✦ LIBER ✦

PDB50 MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES

✍ Scribed by L Annemans; M Lamotte; JJ Caro; V Lavaud; C Nicholls; P McEwan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV80 DERIVING UTITLITY VALUES FOR USE I

✍ P McEwan; C Nicholls; D Getsios; JJ Caro 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCV75 DERIVING COST INPUT VALUES FOR USE

✍ P McEwan; C Nicholls; JJ Caro 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Efficacy and tolerability of rimonabant

✍ André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaa 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 217 KB

PDB50 Long-Term Clinical and Economic Be

✍ W.C. Lee; Y. Samyshkin; J. Langer; J.L. Palmer 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Immediate and long-term effects of addit

✍ Marieke Snel; Janna A. van Diepen; Theo Stijnen; Hanno Pijl; Johannes A. Romijn; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Clinical and economical consequences of

✍ Sicras Mainar, A.; Roldán Suárez, C.; Font Ramos, B.; Navarro Artieda, R.; Ibáñe 📂 Article 📅 2013 🏛 Elsevier ⚖ 517 KB